Mylan Needs Help from FDA to Escape its Woes

Mylan Needs Help from FDA to Escape its Woes


Mylan NV's woes winning federal approval for two potentially profit-driving generics shows how hard a time drugmakers have launching "biosimilars" to rival complex biologic drugs that have been fattening the bottom lines of their competitors. On Wednesday, Aug. 9, Mylan reported second-quarter numbers that came in below analysts' estimates amid pricing pressures facing generics makers.



from Biotech News